Patents by Inventor Kenneth M. Snader

Kenneth M. Snader has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7834005
    Abstract: Disclosed are compounds of Formula I wherein X, Y, R1-R7, T1, T2, Z, and p are as described herein; a pharmaceutical composition comprising a compound of Formula I and a carrier; a method of inhibiting growth of a cell, which method comprises administering in an amount effective to inhibit growth a compound of Formula I; a method of treating cancer in a mammal, which method comprises administering in an amount effective to treat cancer a compound of Formula I; a method of treating a viral, parasitic, or bacterial infection of a cell, which method comprises administering in an amount effective to treat a viral, parasitic, or bacterial infection a compound of Formula I; and a method of preparing a compound of Formula I as described herein.
    Type: Grant
    Filed: February 13, 2009
    Date of Patent: November 16, 2010
    Assignees: The United States of America as represented by the Department of Health and Human Services, Starks Associates, Inc., Midwest Research Institute, Spirogen, Ltd.
    Inventors: Paul S. Liu, B. Rao Vishnuvajjala, Kenneth M. Snader, David E. Thurston, Philip W. Howard, Luke Y. Hsiao, Gregory Turner
  • Publication number: 20090149449
    Abstract: Disclosed are compounds of Formula I wherein X, Y, R1-R7, T1, T2, Z, and p are as described herein; a pharmaceutical composition comprising a compound of Formula I and a carrier; a method of inhibiting growth of a cell, which method comprises administering in an amount effective to inhibit growth a compound of Formula I; a method of treating cancer in a mammal, which method comprises administering in an amount effective to treat cancer a compound of Formula I; a method of treating a viral, parasitic, or bacterial infection of a cell, which method comprises administering in an amount effective to treat a viral, parasitic, or bacterial infection a compound of Formula I; and a method of preparing a compound of Formula I as described herein.
    Type: Application
    Filed: February 13, 2009
    Publication date: June 11, 2009
    Applicants: The United States of America, as represented by the Secretary, Dept. of Health and Human Service, Starks Associates, Inc., Midwest Research Institute, Spirogen, Ltd.
    Inventors: Paul S. Liu, B. Rao Vishnuvajjala, Kenneth M. Snader, David E. Thurston, Philip W. Howard, Luke Y. Hsiao, Gregory Turner
  • Patent number: 7511032
    Abstract: Disclosed are compounds of Formula (I) wherein X, Y, Ri-R7, T1, T2, Z, and p are as described herein; a pharmaceutical composition comprising a compound of Formula (I) and a carrier; a method of inhibiting growth of a cell, which method comprises administering in an amount effective to inhibit growth a compound of Formula (I); a method of treating cancer in a mammal, which method comprises administering in an amount effective to treat cancer a compound of Formula (I); a method of treating a viral, parasitic, or bacterial infection of a cell, which method comprises administering in an amount effective to treat a viral, parasitic, or bacterial infection a compound of Formula (I); and a method of preparing a compound of Formula (I) as described herein.
    Type: Grant
    Filed: October 22, 2004
    Date of Patent: March 31, 2009
    Assignees: The United States of America as represented by the Secretary, Department of Health and Human Services, Starks Associates, Inc., Midwest Research Institute, Spirogen, Ltd.
    Inventors: Paul S Liu, B. Rao Vishnuvajjala, Kenneth M Snader, David E Thurston, Philip W Howard, Luke Y Hsiao, Gregory Turner
  • Patent number: 7244724
    Abstract: A compound of formula I: or solvate thereof, wherein n is 1 to 10, and M and M? are independently selected from monovalent pharmaceutically acceptable cations, or together represent a divalent pharmaceutically acceptable cation.
    Type: Grant
    Filed: May 13, 2005
    Date of Patent: July 17, 2007
    Assignees: United States of America, Represented by the Secretary, Department of Health and Human Services, Spirogen, Ltd.
    Inventors: Paul S. Liu, B. Rao Vishnuvajjala, Kenneth M. Snader, David E. Thurston, Philip Howard, Stephen Gregson
  • Patent number: 6890917
    Abstract: A geldanamycin derivative exhibiting significant preliminary in vivo activity, particularly significant oral in vivo activity, and a method of treating or preventing cancer in a host comprising administering a geldanamycin derivative to a host in an amount sufficient to treat or prevent cancer.
    Type: Grant
    Filed: March 28, 2002
    Date of Patent: May 10, 2005
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Kenneth M. Snader, B. Rao Vishnuvajjala, Melinda G. Hollingshead, Edward A. Sausville
  • Patent number: 6812246
    Abstract: The invention provides an aminoflavone having formula (I), wherein each of R1 and R2 is H, COCH2—R7, wherein R7 is amino alkylamino, dialkylamino, or alkyl- or dialkylaminoalkyl, or an &agr;-amino acid residue, provided that at least one of R1 or R2 is other than H, and R3 is H, branched or straight-chain alkyl, hydroxyalkyl, alkanoyloxyalkyl, alkanoyloxy, alkoxy, or alkoxyalkyl, or pharmaceutically acceptable salts thereof. The present invention also provides a pharmaceutical composition comprising an aminoflavone as described above, and a method of inhibiting the growth of a tumor in a host by administering a tumor growth-inhibiting amount of an aminoflavone compound having the formula as described above.
    Type: Grant
    Filed: June 12, 2003
    Date of Patent: November 2, 2004
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Kenneth M. Snader, B. Rao Vishnuvajjala, Tsutomu Akama
  • Publication number: 20040053909
    Abstract: A geldanamycin derivative exhibiting significant preliminary in vivo activity, particularly significant oral in vivo activity, and a method of treating or preventing cancer in a host comprising administrering a geldanamycin derivative to a host in an amount sufficient to treat or prevent cancer.
    Type: Application
    Filed: September 16, 2003
    Publication date: March 18, 2004
    Inventors: Kenneth M. Snader, B. Rao Vishnuvajjala, Melinda G. Hollingshead, Edward A. Sausville
  • Publication number: 20040019227
    Abstract: The invention provides an aminoflavone having formula (I), wherein each of R1 and R2 is H, COCH2—R7, wherein R7 is amino alkylamino, dialkylamino, or alkyl- or dialkylaminoalkyl, or an &agr;-amino acid residue, provided that at least one of R1 or R2 is other than H, and R3 is H, branched or straight-chain alkyl, hydroxyalkyl, alkanoyloxyalkyl, alkanoyloxy, alkoxy, or alkoxyalkyl, or pharmaceutically acceptable salts thereof. The present invention also provides a pharmaceutical composition comprising an aminoflavone as described above, and a method of inhibiting the growth of a tumor in a host by administering a tumor growth-inhibiting amount of an aminoflavone compound having the formula as described above.
    Type: Application
    Filed: June 12, 2003
    Publication date: January 29, 2004
    Inventors: Kenneth M. Snader, B. Rao Vishnuvajjala, Tsutomu Akama
  • Patent number: 5283383
    Abstract: The present invention relates to a new antitumor compound, a method for isolating same from a red alga, antitumor compositions containing same and methods of using same for treating patients with cancer. The compound of the present invention is 6(R)-bromo-3(S)-bromomethyl-7-methyl-2,3,7-trichloro-1-octene.
    Type: Grant
    Filed: February 18, 1992
    Date of Patent: February 1, 1994
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Michael R. Boyd, John H. Cardellina, II, Richard W. Fuller, Kenneth M. Snader, Jon Clardy
  • Patent number: 4942180
    Abstract: This invention relates to antitumor compositions, and a method for inhibiting, remitting or controlling the growth of tumors or tumor cells utilizing antitumor compositions. More particularly, the antitumor compositions comprise, as active ingredient, an antitumor effective amount of halogenated chamigrenes extracted and derived from red alga and sea hares which diet upon red alga.
    Type: Grant
    Filed: September 4, 1985
    Date of Patent: July 17, 1990
    Assignee: Harbor Branch Oceanographic Institution, Inc.
    Inventors: Tatsuo Higa, Kenneth M. Snader
  • Patent number: 4921873
    Abstract: This invention relates to antiviral and antitumor compositions, a process for producing the compositions and a method for inhibiting viruses and tumors utilizing the compositions. More particularly, the compositions are cyclohexadienone derivatives which are derived from red alga Desmia hornemanni.
    Type: Grant
    Filed: June 14, 1985
    Date of Patent: May 1, 1990
    Assignee: Harbor Branch Oceanographic Institution, Inc.
    Inventors: Tatsuo Higa, Kenneth M. Snader
  • Patent number: 4902716
    Abstract: This invention relates to antiviral compositions, a process for producing the compositions and a method for inhibiting viruses utilizing the compositions. More particularly, the compositions are halogenated chamigrenes extracted from sea hares which diet upon red algae.
    Type: Grant
    Filed: December 18, 1984
    Date of Patent: February 20, 1990
    Assignee: Harbor Branch Oceanographic Institutuion, Inc.
    Inventors: Tatsuo Higa, Kenneth M. Snader
  • Patent number: 4778846
    Abstract: A novel process for the isolation and purification of vancomycin class antibiotics which utilized affinity chromatography by the formation of a sorption complex between the antibiotic and an immobilizing ligand selected from -D-alanyl-D-alanine or -X-D-alanyl-D-alanine, wherein X is an amino acid radical and the novel affinity chromatography sorbent employed therein are disclosed.
    Type: Grant
    Filed: February 4, 1987
    Date of Patent: October 18, 1988
    Assignee: Smithkline Beckman Corporation
    Inventors: Robert D. Sitrin, Kenneth M. Snader, Gail F. Wasserman
  • Patent number: 4708962
    Abstract: This invention relates to antitumor compositions, and a method for inhibiting, remitting or controlling the growth of tumors or tumor cells utilizing antitumor compositions. More particularly, the antitumor compositions comprise, as active ingredient, an antitumor effective amount of halogenated chamigrenes extracted and derived from red alga and sea hares which diet upon red alga.
    Type: Grant
    Filed: September 4, 1985
    Date of Patent: November 24, 1987
    Assignee: Harbor Branch Oceanographic Institution, Inc.
    Inventors: Tatsuo Higa, Kenneth M. Snader
  • Patent number: 4667024
    Abstract: A novel process for the isolation and purification of vancomycin class antibiotics which utilized affinity chromatography by the formation of a sorption complex between the antibiotic and an immobilizing ligand selected from -D-alanyl-D-alanine or -X-D-alanyl-D-alanine, wherein X is an amino acid radical and the novel affinity chromatography sorbent employed therein are disclosed.
    Type: Grant
    Filed: July 13, 1983
    Date of Patent: May 19, 1987
    Assignee: SmithKline Beckman Corporation
    Inventors: Robert D. Sitrin, Kenneth M. Snader, Gail F. Wasserman
  • Patent number: 4385122
    Abstract: A novel anthracycline antibiotic complex, fragilomycin complex, is produced by the cultivation of a fermentation broth containing Streptosporangium fragile Shearer sp. nov. ATCC 31519 microorganisms in an aqueous nutrient medium under submerged aerobic conditions. The fragilomycin complex and its major bioactive component, fragilomycin A, exhibit antibiotic activity.
    Type: Grant
    Filed: August 21, 1981
    Date of Patent: May 24, 1983
    Assignee: SmithKline Beckman Corporation
    Inventors: Claude H. Nash, III, Marcia C. Shearer, Kenneth M. Snader, Joseph R. Valenta, David Cooper
  • Patent number: 4293546
    Abstract: A novel anthracycline antibiotic complex, fragilomycin complex, is produced by the cultivation of a fermentation broth containing Streptosporangium fragilis Shearer sp. nov. ATCC 31519 microorganisms in an aqueous nutrient medium under submerged aerobic conditions. The fragilomycin complex and its major bioactive component, fragilomycin A, exhibit antibiotic activity.
    Type: Grant
    Filed: July 24, 1980
    Date of Patent: October 6, 1981
    Assignee: SmithKline Corporation
    Inventors: Claude H. Nash, III, Marcia C. Shearer, Kenneth M. Snader, Joseph R. Valenta, David Cooper
  • Patent number: 4292305
    Abstract: Imidodisulfamide derivatives useful in the treatment of allergic conditions are prepared by reaction of an appropriately substituted primary amine and bis(chlorosulfonyl) imide in the presence of a tertiary amine.
    Type: Grant
    Filed: February 13, 1980
    Date of Patent: September 29, 1981
    Assignee: SmithKline Corporation
    Inventors: Fadia E. Ali, Robert D. Krell, Kenneth M. Snader
  • Patent number: 4165365
    Abstract: Substituted 2H-pyran-2,6(3H)-dione derivatives useful in the treatment of allergic conditions are prepared by reaction of 3,5-diacetyl-4,6-dihydroxy-2H-pyran-2-one with an appropriate aniline.
    Type: Grant
    Filed: March 10, 1978
    Date of Patent: August 21, 1979
    Assignee: SmithKline Corporation
    Inventor: Kenneth M. Snader
  • Patent number: 4160021
    Abstract: Substituted 2H-pyran-2,6(3H)-dione derivatives useful in the treatment of allergic conditions are prepared by reaction of 3,5-diacetyl-4,6-dihydroxy-2H-pyran-2-one with an appropriate aniline.
    Type: Grant
    Filed: March 10, 1978
    Date of Patent: July 3, 1979
    Assignee: SmithKline Corporation
    Inventor: Kenneth M. Snader